Regeneron, Sage, Tara, Alnylam, & More
Summary
We’ve got those stories and more below: —Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) and its partner Sanofi are ready to take their closely watched allergy drug, dupilumab, into Phase 3 testing after it hit its mark in another mid-stage trial—this time for patients with uncontrolled moderate-to-severe asthma.I spoke with CEO Misti Ushio, a managing director of the VC firm that seeded Tara—Harris & Harris Group (NASDAQ: TINY)—about the technology and how it compares to others in the field.Ophthotech paid Aveo $500,000 up front to investigate tivozanib—once on the doorstep of FDA approval as a kidney cancer drug, before an advisory panel shot it down—as a potential treatment for eye diseases.The deal is badly needed positive news for Aveo, which has lost partnerships with Astellas Pharma and Biogen Idec over the past couple years.—Cambridge-based Alnylam Pharmaceuticals (NASDAQ: ALNY) reported data from a Phase 2 study of revusiran, its subcutaneous RNAi drug, in patients with transthyretin cardiac amyloidosis.
Classifications
AskAI Classifications
LabelsLinked Companies
